San Francisco – September 10, 2026 -- Hagens Berman Sobol Shapiro LLP has filed a securities class action against Regeneron Pharmaceuticals (NASDAQ: REGN) after the failure of a Phase 3 melanoma trial wiped out $11 billion in market capitalization. The suit covers investors who purchased Regeneron shares between August 1, 2025, and May 15, 2026, with a lead plaintiff deadline set for September 14, 2026.

San Francisco – September 10, 2026 -- Investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) have until September 28, 2026, to seek lead plaintiff status in a securities class action tied to the company's Duchenne muscular dystrophy therapy, deramiocel, as the FDA extends its review timeline.

Sheridan, Wyo. – September 10, 2026 -- The global stem cells market is projected to expand from USD 18.9 billion in 2026 to USD 32.57 billion by 2031, growing at a compound annual rate of 11.5%, according to a new study by Wissen Research.

San Francisco – September 10, 2026 -- Hagens Berman Sobol Shapiro LLP has opened an investigation into Aardvark Therapeutics, Inc. (NASDAQ: AARD) over allegations that the company misled investors about the safety of its lead drug candidate ARD-101, ahead of an October 13, 2026 deadline for shareholders to seek lead plaintiff status in a pending securities class action.

Bangkok -- September 7, 2026 -- Wooree Group, a South Korean biotechnology and lighting conglomerate with 60 years of history, has called for a scientific validation standard for the liposomal health products market, following its participation in Vitafoods Asia 2026 held September 2-4 in Bangkok.

Seoul – September 09, 2026 -- The Ministry of Food and Drug Safety of Korea (MFDS) concluded the 12th Global Bio Conference (GBC) on August 28, drawing roughly 5,600 participants from 19 countries to the Grand InterContinental Seoul Parnas for three days of talks on biopharmaceutical regulation and technology.

Hamilton, Ontario – – September 09, 2026 -- AtomVie Global Radiopharma has officially opened a new manufacturing plant at 10 Aeropark Boulevard in Hamilton, Ontario, representing an investment exceeding $160 million and marking the largest contract development and manufacturing organization (CDMO) site in North America dedicated to radiopharmaceutical production.

Hamilton, Ontario – September 09, 2026 -- AtomVie Global Radiopharma has opened a new 72,300-square-foot production facility at 10 Aeropark Boulevard in Hamilton, Ontario, backed by more than $160 million in investment and marking the largest single-site radiopharmaceutical CDMO facility in North America.

Cambridge, Massachusetts – September 09, 2026 -- Insilico Medicine has published data in Nature Biotechnology showing that its AI-designed idiopathic pulmonary fibrosis (IPF) candidate rentosertib reversed predicted biological age by up to six years in some patients, based on six independently developed proteomic aging clocks.

Yantai – September 09, 2026 -- CelluPro has become the first China-based cell culture media supplier to receive EXCiPACTTM GMP certification for pharmaceutical excipients, strengthening its position in global biopharmaceutical supply chains.